Abstract: Disclosed is a digital measurement apparatus including a mounting part on which a measurement object is placed; and a measuring part for measuring the length of the measurement object and providing the measurement value of the measured measurement object as a reference value for adjusting the length of a new measurement object, wherein the measuring part measures the length of the measurement object using any one selected from among a moving method of converting a distance moved due to interference with the measurement object placed on the mounting part; a radiation method of radiating a measurement signal toward the measurement object and converting information of the detected measurement signal into the length of the measurement object; and a scanning method of scanning the measurement object. With this configuration, accuracy in measuring the length of a measurement object may be improved using a simple structure.

Abstract: Provided herein are chimeric antigen receptors (CARs), cells comprising the CARs, monoclonal and bispecific antibodies or antigen-binding fragments thereof, and kits comprising the same. The CARs and bispecific antibodies are designed to target at least one tumor antigen and at least one tumor in methods of treating cancer in subjects in need thereof.

Abstract: The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Abstract: The present disclosure discloses a microscopic device (100, 1400, 1900) and an image processing device (1500). The image processing device (1500) includes a receiving device (1501) configured to receive a digital image generated by the microscopic device (100, 1400, 1900), the digital image includes a scaling pattern (202, 302, 402, 502, 702, 802, 902, 1002); a storage device (1502) configured to store the digital image; and a processor (1503) configured to determine a magnification of the microscopic device (100, 1400, 1900) based on the scaling pattern (202, 302, 402, 502, 702, 802, 902, 1002).

Abstract: The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLR8, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency.

Abstract: A microneedle chip and manufacturing method. The method comprises injecting, into a female mold, a fluid needle liquid, wherein forming cavities matching the shapes of needles of a microneedle chip are provided at the female mold and form a cavity array, injection inlets are provided at a surface of one side of the female mold, and air ejection openings are provided at a surface of another side of the female mold to form an air ejection surface; covering the air ejection surface of the female mold using a breathable film, and during injection, passing a gas through the breathable film so as to retain the liquid inside the forming cavities; curing the fluid needle liquid to form the microneedle chip, and demolding to obtain the same. By employing the air ejection openings and the breathable film, a liquid is retained while ejecting a gas, providing a favorable micro-injection effect.

Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.

Abstract: Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.

Abstract: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

Abstract: Described are embodiments of a multilaminate or multiple layer implantable surgical graft with an illustrative graft comprising a remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members.

Abstract: A cocrystal containing the 1?R-diastereomer and the 1?S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1?R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.

Abstract: The present disclosure relates to an immunoconjugate including an antibody, or antigen binding fragment thereof, that specifically binds to CD300f, linked to at least one cytotoxic agent, and to compositions including the immunoconjugate, and use of the immunoconjugate for depleting haematopoietic stem and progenitor cells, for preparing a subject haematopoietic stem cell transplantation, and for the treatment of CD300f associated conditions.

Abstract: The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Abstract: The present disclosure provides a cell separation apparatus for a bioreactor. The cell separation apparatus may be disposed outside the bioreactor and in fluid connection with the bioreactor, the cell separation apparatus may be in a shape of a box body, the cell separation apparatus may include a liquid buffer device including a first liquid cavity disposed in the box body; a filter device including a filter channel and a filter membrane disposed in the box body, the filter membrane may be disposed above the filter channel; and a first liquid channel may be configured in the box body to facilitate a fluid communication between the first liquid cavity and the filter channel. A power system for filtering and microfluidic channels are integrated in the cell separation apparatus that is of a box shape, thereby reducing the volume and production cost thereof.

Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.

Abstract: Disclosed herein is an apparatus for facilitating purification of sludge and tailing, in accordance with some embodiments. Accordingly, a sedimentation unit receives sludge and tailing in a first tank, separates wastewater from the sludge and the tailing, and transfers the wastewater from the first tank to a second tank. Further, a centrifugal unit creates a vortex in the wastewater. Further, a thermal hydrolysis unit coagulates a second impurity of the wastewater using coagulants and transfers the wastewater from the second tank to a third tank. Further, a digesting unit digests a macromolecule of the wastewater into a compound and transfers the wastewater from the third tank to a fourth tank. Further, a nutrient removal unit filters the wastewater from the compound and transfers the wastewater from the fourth tank to a fifth tank. Further, a reservoir unit disinfects the wastewater and stores the wastewater in the fifth tank.

Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.